EWM
TVTX icon

Evolution Wealth Management’s Travere Therapeutics TVTX Stock Holding History

Evolution Wealth Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.97K Hold
100
– – ﹤0.01% 690
2025
Q4 		$3.82K Buy
+100
New +$3.25K ﹤0.01% 577

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Evolution Wealth Management's TVTX Position: Q1 2026 in Review

Evolution Wealth Management held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 100 shares worth $2.97K. The position accounts for ﹤0.01% of the portfolio, ranked #690.

Evolution Wealth Management first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.82K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Evolution Wealth Management held 100 shares of Travere Therapeutics worth $2.97K as of Q1 2026.
  • Evolution Wealth Management left its Travere Therapeutics share count unchanged in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of Evolution Wealth Management's portfolio in Q1 2026, its #690 holding.
  • Evolution Wealth Management first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Evolution Wealth Management's Travere Therapeutics position peaked at $3.82K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Evolution Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.